Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower

NCT05162768 is registered in ClinicalTrials.gov with Stealth BioTherapeutics Inc. as lead sponsor.

NCT NCT05162768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower
Lead sponsor
Stealth BioTherapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2022
Completion date
December 4, 2024
Enrollment
102 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

mitochondrial complex i deficiency, mitochondrial diseases, mitochondrial dna deletion, mitochondrial dna depletion, mitochondrial dna mutation, mitochondrial metabolism defect, mitochondrial myopathies, mitochondrial pathology